HIV-1 and SARS-CoV-2: Patterns in the evolution of two pandemic pathogens

W Fischer, EE Giorgi, S Chakraborty, K Nguyen… - Cell host & …, 2021 - cell.com
Humanity is currently facing the challenge of two devastating pandemics caused by two very
different RNA viruses: HIV-1, which has been with us for decades, and SARS-CoV-2, which …

Latency reversal and viral clearance to cure HIV-1

DM Margolis, JV Garcia, DJ Hazuda, BF Haynes - Science, 2016 - science.org
BACKGROUND A central challenge to emerging efforts to cure HIV infection is the
persistence of quiescent but replication-competent proviral genomes in resting CD4+ T …

Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations

K Deng, M Pertea, A Rongvaux, L Wang, CM Durand… - Nature, 2015 - nature.com
Despite antiretroviral therapy (ART), human immunodeficiency virus (HIV)-1 persists in a
stable latent reservoir,, primarily in resting memory CD4+ T cells,. This reservoir presents a …

[HTML][HTML] Magnitude and kinetics of CD8+ T cell activation during hyperacute HIV infection impact viral set point

ZM Ndhlovu, P Kamya, N Mewalal, HN Kløverpris… - Immunity, 2015 - cell.com
CD8+ T cells contribute to the control of HIV, but it is not clear whether initial immune
responses modulate the viral set point. We screened high-risk uninfected women twice a …

Modeling the within-host dynamics of HIV infection

AS Perelson, RM Ribeiro - BMC biology, 2013 - Springer
The new field of viral dynamics, based on within-host modeling of viral infections, began with
models of human immunodeficiency virus (HIV), but now includes many viral infections …

Relative resistance of HIV-1 founder viruses to control by interferon-alpha

AE Fenton-May, O Dibben, T Emmerich, H Ding… - Retrovirology, 2013 - Springer
Background Following mucosal human immunodeficiency virus type 1 (HIV-1) transmission,
type 1 interferons (IFNs) are rapidly induced at sites of initial virus replication in the mucosa …

Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1

N Borthwick, T Ahmed, B Ondondo, P Hayes, A Rose… - Molecular therapy, 2014 - cell.com
Virus diversity and escape from immune responses are the biggest challenges to the
development of an effective vaccine against HIV-1. We hypothesized that T-cell vaccines …

Vaccines and broadly neutralizing antibodies for HIV-1 prevention

KE Stephenson, K Wagh, B Korber… - Annual review of …, 2020 - annualreviews.org
Development of improved approaches for HIV-1 prevention will likely be required for a
durable end to the global AIDS pandemic. Recent advances in preclinical studies and early …

[HTML][HTML] Neopepsee: accurate genome-level prediction of neoantigens by harnessing sequence and amino acid immunogenicity information

S Kim, HS Kim, E Kim, MG Lee, EC Shin, S Paik - Annals of Oncology, 2018 - Elsevier
Background Tumor-specific mutations form novel immunogenic peptides called
neoantigens. Neoantigens can be used as a biomarker predicting patient response to …

HIV-host interactions: implications for vaccine design

BF Haynes, GM Shaw, B Korber, G Kelsoe, J Sodroski… - Cell host & …, 2016 - cell.com
Development of an effective AIDS vaccine is a global priority. However, the extreme diversity
of HIV type 1 (HIV-1), which is a consequence of its propensity to mutate to escape immune …